Company Profile

ASTRAZENECA PHARMA INDIA LTD.

NSE : ASTRAZENBSE : 506820ISIN CODE : INE203A01020Industry : Pharmaceuticals & DrugsHouse : Astrazeneca Pharma India - MNC
BSE3739.00-43.55 (-1.15 % )
PREV CLOSE (Rs.) 3782.55
OPEN PRICE (Rs.) 3768.75
BID PRICE (QTY) 0.00 (0 )
OFFER PRICE (QTY) 0.00 (0 )
VOLUME 2272
TODAY'S LOW / HIGH (Rs.)3715.50 3820.30
52 WK LOW / HIGH (Rs.)2605 4970
NSE3754.90 -31.05 (-0.82 % )
PREV CLOSE(Rs.) 3785.95
OPEN PRICE (Rs.) 3785.95
BID PRICE (QTY) 3754.90 (21 )
OFFER PRICE (QTY) 0.00 (0 )
VOLUME 28490
TODAY'S LOW / HIGH(Rs.) 3750.00 3820.00
52 WK LOW / HIGH (Rs.)2595 4970

Smart Quotes

1D 1M 3M 1Y 3Y 5Y
STOCK SUMMARY
Trade Value (Rs. in Lacs) 0.00
Dividend Yield(%) 0.03
TTM EPS (Rs.) 30.24
P/E Ratio 124.20
Book Value (Rs.) 162.01
Face Value (Rs.) 2
MCap (Rs. in Mn) 93900.00
Price/Earning (TTM) 99.43
Price/Sales (TTM) 11.76
Price/Book (MRQ) 23.18
PAT Margin (%) 8.68
ROCE (%) 34.61
Incorporation Year : 1979

Management Info :

Narayan K Seshadri - Chairman Gagandeep Singh Bedi - Managing Director

Registered Office :

Address : Block N1, 12th Floor,Manyata Embassy Business Park,Rachenahalli, Outer Ring Road,
Bengaluru,
Karnataka-560045

Phone :

Registrar's Details : Integrated Registrary Management Services Pvt Ltd.-(Formerly Integrated Enterprises (India) Ltd)
30, Ramana Residency,4th Cross, Sampige Road,Malleswaram,Bangalore
Listing : BSE, NSE, MCX
NEWS More
22Apr04-22-2021$ Launch Of Benralizumab 30Mg/Ml Solution For Injection (Fasenra?) Launch Of Benralizumab 30Mg
We refer to our earlier communication dated December 20, 2020 intimating the receipt of Import and Market Permission in Form CT-20 (Marketing Authorization- Additional Indication) from the Drugs Controller General of India for Benralizumab 30mg/mL solution for injection (Fasenra?) With regard to the same, we now wish to further update that AstraZeneca Pharma India Limited has launched Fasenra? in India on April 20, 2021. Benralizumab (Fasenra?) is indicated as an add-on maintenance treatment for severe asthma with an eosinophilic phenotype in adult patients.
We refer to our earlier communication dated December 20, 2020 i..
22Apr04-22-2021$AstraZeneca Pharma India surges on launching Fasenra in India AstraZeneca Pharma India sur

Astrazeneca Pharma India is currently trading at Rs. 3905.70, up by 314.95 points or 8.77% from its previous closing of Rs. 3590.75 on the BSE.

The scrip opened at Rs. 3735.00 and has touched a high and low of Rs. 3971.00 and Rs. 3713.50 respectively. So far 34234 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 4970.00 on 08-Sep-2020 and a 52 week low of Rs. 2540.00 on 22-Apr-2020.

Last one week high and low of the scrip stood at Rs. 3971.00 and Rs. 3410.00 respectively. The current market cap of the company is Rs. 9764.25 crore.

The promoters holding in the company stood at 75.00%, while Institutions and Non-Institutions held 3.82% and 21.18% respectively.

AstraZeneca Pharma India has launched Fasenra in India. Benralizumab (Fasenra) is indicated as an add-on maintenance treatment for severe asthma with an eosinophilic phenotype in adult patients.

Earlier, the company had received Import and Market Permission in Form CT-20 (Marketing Authorization- Additional Indication) from the Drugs Controller General of India for Benralizumab 30mg/mL solution for injection (Fasenra).

AstraZeneca Pharma India is a global biopharmaceutical company. The company is engaged in the discovery, development and commercialization of medicines for core areas of healthcare, including cardiovascular/metabolic disease, cancer and respiratory, inflammatory and autoimmune disease. The company operates through two segments Healthcare and Clinical Trial.

Astrazeneca Pharma India is currently trading at Rs. 3905.70, u..
22Apr04-22-2021$Hero MotoCorp, Maruti Suzuki and KEC International to see some action today Hero MotoCorp, Maruti Suzuki

Hero MotoCorp and Gogoro Inc. have entered into strategic partnership to accelerate the shift to sustainable electric mobility in India. The partnership brings together the company and Gogoro, the global leader in urban battery swapping and smart mobility innovation.

Maruti Suzuki India's -- Cargo Variants of EECO have been upgraded to new version of Reverse Park Alert Systems (RPAS) system. The revised Ex-showroom price applicable in Delhi shall vary from approximately Rs 4.27 lakh to Rs 5.49 lakh. The same is effective from April 21, 2021.

KEC International has won new orders of Rs 1,245 crore across various businesses. The transmission and distribution business secured orders of Rs 629 crore for projects in India, SAARC, Middle East, Africa and the Americas.

Lupin has incorporated a wholly-owned subsidiary in the USA under the name ‘Lupin Oncology Inc.’ (LOI). This wholly owned subsidiary will be engaged in development/co-development and commercialization of multiple oncology products globally. LOI will be pursuing partners, financial sponsors and perform such other acts as may be necessary.

AstraZeneca Pharma India has launched Fasenra in India. Benralizumab (Fasenra) is indicated as an add-on maintenance treatment for severe asthma with an eosinophilic phenotype in adult patients.

LIC Housing Finance’s parent organization -- Life Insurance Corporation (LIC) has collected new premiums of Rs 1.84 lakh crore in FY21. It also paid out Rs 1.34 lakh crore as claims during the year. Despite Coronavirus outbreak where there was a nationwide lockdown imposed during Q1FY21, this is its highest ever new premium collection by LIC.

GE Power India has completed acquisition of 50% of the issued and paid up share capital of NTPC GE Power Services (NGSL) on April 19, 2021. Earlier, the company’s board had approved the acquisition of 50% of the issued and paid-up share capital of NGSL for Rs 7.2 crore. The acquisition of shares of NGSL from GEPower Systems GmbH is a related party transaction as the Company and GE Power Systems GmbH are GE Group Affiliates.

Hero MotoCorp and Gogoro Inc. have entered into strategic partn..
21Apr04-21-2021$AstraZeneca Pharma India launches Fasenra in India AstraZeneca Pharma India lau

AstraZeneca Pharma India has launched Fasenra in India. Benralizumab (Fasenra) is indicated as an add-on maintenance treatment for severe asthma with an eosinophilic phenotype in adult patients.

Earlier, the company had received Import and Market Permission in Form CT-20 (Marketing Authorization- Additional Indication) from the Drugs Controller General of India for Benralizumab 30mg/mL solution for injection (Fasenra).

AstraZeneca Pharma India is a global biopharmaceutical company. The company is engaged in the discovery, development and commercialization of medicines for core areas of healthcare, including cardiovascular/metabolic disease, cancer and respiratory, inflammatory and autoimmune disease. The company operates through two segments Healthcare and Clinical Trial.

AstraZeneca Pharma India has launched Fasenra in India. Benrali..
11Mar03-11-2021$AstraZeneca Pharma receives import, market permission for Osimertinib film coated tablets AstraZeneca Pharma receives

AstraZeneca Pharma India has received Import and Market Permission in Form CT-20 (Subsequent New Drug Approval) from the Drugs Controller General of India for Osimertinib 40mg/80mg film coated tablets (Tagrisso).

Osimertinib 40mg/80mg film coated tablets as monotherapy is now approved for additional indication for the adjuvant treatment after complete tumour resection in patients with non-small cell lung cancer (NSCLC) whose tumours have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations.

The receipt of this permission paves way for the launch of Osimertinib 40mg/80mg film coated tablets into a new disease area in India, subject to the receipt of related statutory approvals and licenses.

AstraZeneca Pharma India is a global biopharmaceutical company. The company is engaged in the discovery, development and commercialization of medicines for core areas of healthcare, including cardiovascular/metabolic disease, cancer and respiratory, inflammatory and autoimmune disease. The company operates through two segments Healthcare and Clinical Trial.

AstraZeneca Pharma India has received Import and Market Permiss..
Financials More
Rs. in Millions
QTR Dec 20 ANNUAL 20
Net Profit210.52722.1
Gross Profit 283.01 1139.6
Operating Profit 336.711336.81
Net Sales 2002.528318.09
ROLLING FORWARD P/E (EOD)
EVENT CALENDAR
peer group More
NGL Fine-Chem (BSE)
 1679.60 (4.62%)
M.Cap ( in Cr)
1037.66
Ajanta Pharma (BSE)
 2002.95 (3.11%)
M.Cap ( in Cr)
17398.94
Solara Active Pharma (BSE)
 1742.70 (2.80%)
M.Cap ( in Cr)
6280.52
Themis Medicare (BSE)
 465.55 (5.54%)
M.Cap ( in Cr)
440.91
Cadila Healthcare (BSE)
 646.95 (2.74%)
M.Cap ( in Cr)
66231.03
Shareholding Pattern More
PROMOTERS 75 %
NON-INSTITUTION 21.64 %
MUTUAL FUNDS/UTI 0.83 %
FI/BANKS/INSURANCE 0 %
GOVERNMENT 0 %
FII 0 %
F & O Quotes